What are the main indications for dose reduction with eribulin?
When I consider dose reducing eribulin, the reasons that most commonly are encountered are myelosuppression, so a low neutrophil count on the day of treatment, which can also be addressed by the insertion of growth factors, such as G-CSF, Neupogen, or Neulasta. So that's not always a reason for dose reduction.
For me, more commonly the reason for dose reduction is either peripheral neuropathy, which was the most common reason for dose reduction in the randomized trial, but also fatigue. Fatigue is a very difficult symptom to tease out in a population of metastatic breast cancer patients receiving their third line of chemotherapy.
Triple Negative Breast Cancer: Case 1
Christine H is a 54-year-old stay-at-home-mother who works part time as a real estate agent. Medical history is notable for hypertension (well controlled) and surgery for aortic aneurysm in 2011
In September 2013, she presented to her PCP with a right breast lump; mammogram showed a large primary breast mass and two enlarged axillary lymph nodes.
At her follow-up in May 2014, the patient showed progression of the right chest wall metastases, and several new liver lesions were detected.
In December of 2014, she presented with increasing fatigue and chest pain on follow up and her CT scan was consistent with progression of the hepatic metastases, with several new lesions also noted in the lungs; her ECOG performance status (PS) at the time was 1.
Inavolisib Combo Meets Primary End Point in PIK3CA-Mutated Breast Cancer
December 5th 2023An experimental drug combination of inavolisib, palbociclib, and fulvestrant significantly improved progression-free survival in patients with HR-positive/HER2-negative PIK3CA-mutated breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Navigating HER2+ Early Breast Cancer: Insights Into the Current Treatment Landscape
November 28th 2023In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.
Read More